ダウンロード数: 40
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
cas.14935.pdf | 1.69 MB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Okasho, Kosuke | en |
dc.contributor.author | Mizuno, Kei | en |
dc.contributor.author | Fukui, Tomohiro | en |
dc.contributor.author | Lin, Yen‐Yi | en |
dc.contributor.author | Kamiyama, Yuki | en |
dc.contributor.author | Sunada, Takuro | en |
dc.contributor.author | Li, Xin | en |
dc.contributor.author | Kimura, Hiroko | en |
dc.contributor.author | Sumiyoshi, Takayuki | en |
dc.contributor.author | Goto, Takayuki | en |
dc.contributor.author | Kobayashi, Takashi | en |
dc.contributor.author | Lin, Dong | en |
dc.contributor.author | Wang, Yuzhuo | en |
dc.contributor.author | Collins, Colin C. | en |
dc.contributor.author | Inoue, Takahiro | en |
dc.contributor.author | Ogawa, Osamu | en |
dc.contributor.author | Akamatsu, Shusuke | en |
dc.contributor.alternative | 岡所, 広祐 | ja |
dc.contributor.alternative | 水野, 桂 | ja |
dc.contributor.alternative | 福井, 智洋 | ja |
dc.contributor.alternative | 上山, 裕樹 | ja |
dc.contributor.alternative | 砂田, 拓郎 | ja |
dc.contributor.alternative | 李, 新 | ja |
dc.contributor.alternative | 木村, 博子 | ja |
dc.contributor.alternative | 住吉, 崇幸 | ja |
dc.contributor.alternative | 後藤, 崇之 | ja |
dc.contributor.alternative | 小林, 恭 | ja |
dc.contributor.alternative | 小川, 修 | ja |
dc.contributor.alternative | 赤松, 秀輔 | ja |
dc.date.accessioned | 2022-12-22T07:23:34Z | - |
dc.date.available | 2022-12-22T07:23:34Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.uri | http://hdl.handle.net/2433/277917 | - |
dc.description.abstract | The prevalence of neuroendocrine prostate cancer (NEPC) arising from adenocarcinoma (AC) upon potent androgen receptor (AR) pathway inhibition is increasing. Deeper understanding of NEPC biology and development of novel therapeutic agents are needed. However, research is hindered by the paucity of research models, especially cell lines developed from NEPC patients. We established a novel NEPC cell line, KUCaP13, from tissue of a patient initially diagnosed with AC which later recurred as NEPC. The cell line has been maintained permanently in vitro under regular cell culture conditions and is amenable to gene engineering with lentivirus. KUCaP13 cells lack the expression of AR and overexpress NEPC-associated genes, including SOX2, EZH2, AURKA, PEG10, POU3F2, ENO2, and FOXA2. Importantly, the cell line maintains the homozygous deletion of CHD1, which was confirmed in the primary AC of the index patient. Loss of heterozygosity of TP53 and PTEN, and an allelic loss of RB1 with a transcriptomic signature compatible with Rb pathway aberration were revealed. Knockdown of PEG10 using shRNA significantly suppressed growth in vivo. Introduction of luciferase allowed serial monitoring of cells implanted orthotopically or in the renal subcapsule. Although H3K27me was reduced by EZH2 inhibition, reversion to AC was not observed. KUCaP13 is the first patient-derived, treatment-related NEPC cell line with triple loss of tumor suppressors critical for NEPC development through lineage plasticity. It could be valuable in research to deepen the understanding of NEPC. | en |
dc.language.iso | eng | - |
dc.publisher | Wiley | en |
dc.rights | © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. | en |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.subject | cell line | en |
dc.subject | cultured tumor cells | en |
dc.subject | neuroendocrine tumor | en |
dc.subject | prostate cancer | en |
dc.subject | xenograft | en |
dc.title | Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13 | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | Cancer Science | en |
dc.identifier.volume | 112 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 2781 | - |
dc.identifier.epage | 2791 | - |
dc.relation.doi | 10.1111/cas.14935 | - |
dc.textversion | publisher | - |
dc.identifier.pmid | 33960594 | - |
dcterms.accessRights | open access | - |
dc.identifier.pissn | 1347-9032 | - |
dc.identifier.eissn | 1349-7006 | - |
出現コレクション: | 学術雑誌掲載論文等 |
このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス